These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29506079)

  • 1. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
    Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
    J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landscape of Somatic Genetic Alterations in Breast Cancers from
    Mandelker D; Kumar R; Pei X; Selenica P; Setton J; Arunachalam S; Ceyhan-Birsoy O; Brown DN; Norton L; Robson ME; Wen HY; Powell S; Riaz N; Weigelt B; Reis-Filho JS
    JNCI Cancer Spectr; 2019 Jun; 3(2):pkz027. PubMed ID: 31360903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Yang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Zhang J; Xie Y
    Breast Cancer Res Treat; 2019 Apr; 174(3):639-647. PubMed ID: 30607632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Almost 2% of Spanish breast cancer families are associated to germline pathogenic mutations in the ATM gene.
    Tavera-Tapia A; Pérez-Cabornero L; Macías JA; Ceballos MI; Roncador G; de la Hoya M; Barroso A; Felipe-Ponce V; Serrano-Blanch R; Hinojo C; Miramar-Gallart MD; Urioste M; Caldés T; Santillan-Garzón S; Benitez J; Osorio A
    Breast Cancer Res Treat; 2017 Feb; 161(3):597-604. PubMed ID: 27913932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study.
    Bubien V; Bonnet F; Dupiot-Chiron J; Barouk-Simonet E; Jones N; de Reynies A; MacGrogan G; Sevenet N; Letouzé E; Longy M
    Genes Chromosomes Cancer; 2017 Nov; 56(11):788-799. PubMed ID: 28691344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
    Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
    Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
    Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
    Natrajan R; Mackay A; Lambros MB; Weigelt B; Wilkerson PM; Manie E; Grigoriadis A; A'Hern R; van der Groep P; Kozarewa I; Popova T; Mariani O; Turaljic S; Furney SJ; Marais R; Rodruigues DN; Flora AC; Wai P; Pawar V; McDade S; Carroll J; Stoppa-Lyonnet D; Green AR; Ellis IO; Swanton C; van Diest P; Delattre O; Lord CJ; Foulkes WD; Vincent-Salomon A; Ashworth A; Stern MH; Reis-Filho JS
    J Pathol; 2012 May; 227(1):29-41. PubMed ID: 22362584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
    Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
    Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    Nones K; Johnson J; Newell F; Patch AM; Thorne H; Kazakoff SH; de Luca XM; Parsons MT; Ferguson K; Reid LE; McCart Reed AE; Srihari S; Lakis V; Davidson AL; Mukhopadhyay P; Holmes O; Xu Q; Wood S; Leonard C; ; ; ; Beesley J; Harris JM; Barnes D; Degasperi A; Ragan MA; Spurdle AB; Khanna KK; Lakhani SR; Pearson JV; Nik-Zainal S; Chenevix-Trench G; Waddell N; Simpson PT
    Ann Oncol; 2019 Jul; 30(7):1071-1079. PubMed ID: 31090900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
    Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATM germline mutations in women with familial breast cancer and a relative with haematological malignancy.
    Paglia LL; Laugé A; Weber J; Champ J; Cavaciuti E; Russo A; Viovy JL; Stoppa-Lyonnet D
    Breast Cancer Res Treat; 2010 Jan; 119(2):443-52. PubMed ID: 19404735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.
    Broeks A; Urbanus JH; Floore AN; Dahler EC; Klijn JG; Rutgers EJ; Devilee P; Russell NS; van Leeuwen FE; van 't Veer LJ
    Am J Hum Genet; 2000 Feb; 66(2):494-500. PubMed ID: 10677309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous recombination DNA repair defects in
    Li A; Geyer FC; Blecua P; Lee JY; Selenica P; Brown DN; Pareja F; Lee SSK; Kumar R; Rivera B; Bi R; Piscuoglio S; Wen HY; Lozada JR; Gularte-Mérida R; Cavallone L; ; Rezoug Z; Nguyen-Dumont T; Peterlongo P; Tondini C; Terkelsen T; Rønlund K; Boonen SE; Mannerma A; Winqvist R; Janatova M; Rajadurai P; Xia B; Norton L; Robson ME; Ng PS; Looi LM; Southey MC; Weigelt B; Soo-Hwang T; Tischkowitz M; Foulkes WD; Reis-Filho JS
    NPJ Breast Cancer; 2019; 5():23. PubMed ID: 31428676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.
    Prodosmo A; Buffone A; Mattioni M; Barnabei A; Persichetti A; De Leo A; Appetecchia M; Nicolussi A; Coppa A; Sciacchitano S; Giordano C; Pinnarò P; Sanguineti G; Strigari L; Alessandrini G; Facciolo F; Cosimelli M; Grazi GL; Corrado G; Vizza E; Giannini G; Soddu S
    J Exp Clin Cancer Res; 2016 Sep; 35(1):135. PubMed ID: 27599564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Petrackova A; Savara J; Turcsanyi P; Gajdos P; Papajik T; Kriegova E
    Br J Haematol; 2022 Nov; 199(3):371-381. PubMed ID: 36029002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.
    van Os NJ; Roeleveld N; Weemaes CM; Jongmans MC; Janssens GO; Taylor AM; Hoogerbrugge N; Willemsen MA
    Clin Genet; 2016 Aug; 90(2):105-17. PubMed ID: 26662178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants.
    Lim BWX; Li N; Mahale S; McInerny S; Zethoven M; Rowley SM; Huynh J; Wang T; Lee JEA; Friedman M; Devereux L; Scott RJ; Sloan EK; James PA; Campbell IG
    J Natl Cancer Inst; 2023 Feb; 115(2):181-189. PubMed ID: 36315097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.